Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2.
paper
Cited
Public
Unavailable
- Authors
- Takamatsu, Koutaro; Ikeda, Tokunori; Haruta, Miwa; Matsumura, Keiko; Ogi, Yasuhiro; Nakagata, Naomi; Uchino, Makoto; Ando, Yukio; Nishimura, Yasuharu; Senju, Satoru
- Year
- 2014
- Journal
- Stem cell research
- PMID
- 25460605
- DOI
- 10.1016/j.scr.2014.10.001
The purpose of this study was to evaluate the therapeutic potential of human induced pluripotent stem (iPS) cell-derived macrophage-like cells for Alzheimer's disease (AD). In previous studies, we established the technology to generate macrophage-like myeloid lineage cells with proliferating capacity from human iPS cells, and we designated the cells iPS-ML. iPS-ML reduced the level of AΞ² added into the culture medium, and the culture supernatant of iPS-ML alleviated the neurotoxicity of AΞ². We generated iPS-ML expressing the Fc-receptor-fused form of a single chain antibody specific to AΞ². In addition, we made iPS-ML expressing Neprilysin-2 (NEP2), which is a protease with AΞ²-degrading activity. In vitro, expression of NEP2 but not anti-AΞ² scFv enhanced the effect to reduce the level of soluble AΞ² oligomer in the culture medium and to alleviate the neurotoxicity of AΞ². To analyze the effect of iPS-ML expressing NEP2 (iPS-ML/NEP2) in vivo, we intracerebrally administered the iPS-ML/NEP2 to 5XFAD mice, which is a mouse model of AD. We observed significant reduction in the level of AΞ² in the brain interstitial fluid following administration of iPS-ML/NEP2. These results suggested that iPS-ML/NEP2 may be a potential therapeutic agent in the treatment of AD.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | 2018 | 29897633 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Curcumin-enhanced stem cell exosomes: A novel approach to modulating neuroinflammation and improving cognitive function in a rat model of Alzheimer's disease. | Bashirrohelleh MA et al. | β | 2025 | β |
| Epithelial FETUB-mediated the inhibition of NEP activity aggravates asthma. | Sun P et al. | β | 2025 | β |
| Management of Alzheimer's Disease With Nanotechnological Interventions and Novel Therapeutics. | Shahrukh M et al. | β | 2025 | β |
| Stem Cell Interventions in the Treatment of Alzheimer's Disease. | Madhan S et al. | β | 2025 | β |
| Gene therapy: an alternative to treat Alzheimer's disease. | Doshi V et al. | β | 2024 | β |
| Insights into the Identification of iPSC- and Monocyte-Derived Macrophage-Polarizing Compounds by AI-Fueled Cell Painting Analysis Tools. | BrΓΌggenthies JB et al. | β | 2024 | β |
| Proposed Mechanisms of Cell Therapy for Alzheimer's Disease. | Belousova E et al. | β | 2024 | β |
| Stem cell therapy in Alzheimer's disease: current status and perspectives. | Ou CM et al. | β | 2024 | β |
| Valproate Administration to Adult 5xFAD Mice Upregulates Expression of Neprilysin and Improves Olfaction and Memory. | Vasilev DS et al. | β | 2024 | β |
| Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease. | Katta M et al. | β | 2023 | β |
| Experimental approaches for altering the expression of Abeta-degrading enzymes. | Loeffler DA | β | 2023 | β |
| Future prospects for cancer immunotherapy using induced pluripotent stem cell-derived dendritic cells or macrophages. | Fukushima S et al. | β | 2023 | β |
| Microbiota-gut-brain axis and related therapeutics in Alzheimer's disease: prospects for multitherapy and inflammation control. | Li J et al. | β | 2023 | β |
| miRNAs and Stem Cells as Promising Diagnostic and Therapeutic Targets for Alzheimer's Disease. | Elzayat EM et al. | β | 2023 | β |
| Recent advancement in therapeutic strategies for Alzheimer's disease: Insights from clinical trials. | Khan T et al. | β | 2023 | β |
| Advances in stem cell therapy in Alzheimer's disease: a comprehensive clinical trial review. | Karvelas N et al. | β | 2022 | β |
| Application of stem cell biology in treating neurodegenerative diseases. | Jia N et al. | β | 2022 | β |
| Stem Cells as a Potential Therapeutic Option for Treating Neurodegenerative Diseases. | Aishwarya L et al. | β | 2022 | β |
| High-Yield Human Induced Pluripotent Stem Cell-Derived Monocytes and Macrophages Are Functionally Comparable With Primary Cells. | Cui D et al. | β | 2021 | β |
| Recent advances in stem cell therapy for neurodegenerative disease: Three dimensional tracing and its emerging use. | Kim IK et al. | β | 2021 | β |
| Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. | Sivandzade F et al. | β | 2021 | β |
| Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E. | Robert J et al. | β | 2020 | β |
| Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges. | Ford E et al. | β | 2020 | β |
| Large-Scale Production of Human iPSC-Derived Macrophages for Drug Screening. | Gutbier S et al. | β | 2020 | β |
| Stem cell therapy for Alzheimer's disease. | Liu XY et al. | β | 2020 | β |
| Stem Cell Therapy for Alzheimer's Disease. | Han F et al. | β | 2020 | β |
| Human-induced pluripotent stem cell-derived blood products: state of the art and future directions. | Hansen M et al. | β | 2019 | β |
| Important advances in Alzheimer's disease from the use of induced pluripotent stem cells. | Majolo F et al. | β | 2019 | β |
| New treatment modalities in Alzheimer's disease. | Koseoglu E | β | 2019 | β |
| Stem cell therapy in Alzheimer's disease: possible benefits and limiting drawbacks. | Alipour M et al. | β | 2019 | β |
| Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease. | Kwak KA et al. | β | 2018 | β |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | β | 2018 | β |
| Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy. | Clayton KA et al. | β | 2017 | β |
| Cell reprogramming: Therapeutic potential and the promise of rejuvenation for the aging brain. | LΓ³pez-LeΓ³n M et al. | β | 2017 | β |
| Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. | Robert J et al. | β | 2017 | β |
| Stem cell models of Alzheimer's disease: progress and challenges. | Arber C et al. | β | 2017 | β |
| Stem cell therapies in age-related neurodegenerative diseases and stroke. | Wang Y et al. | β | 2017 | β |
| Accelerating stem cell trials for Alzheimer's disease. | Hunsberger JG et al. | β | 2016 | β |
| Human Neural Stem Cell Transplantation Rescues Cognitive Defects in APP/PS1 Model of Alzheimer's Disease by Enhancing Neuronal Connectivity and Metabolic Activity. | Li X et al. | β | 2016 | β |
| Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment. | Suenaga G et al. | β | 2016 | β |
| Pluripotent stem cells: the last 10 years. | Kimbrel EA et al. | β | 2016 | β |
| Stepping back to move forward: a current review of iPSCs in the fight against Alzheimer's disease. | Devineni A et al. | β | 2016 | β |
| Current status of pluripotent stem cells: moving the first therapies to the clinic. | Kimbrel EA et al. | β | 2015 | β |
| Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. | Jha NK et al. | β | 2015 | β |